7 results for tag: R&D
NHS Pays £0.5bn for Public Funded Drugs
Pharmaceutical companies are charging the NHS half a billion pounds a year for cancer treatments discovered with the help of public money. We are paying twice for new medicines. Figures released by the Missing Medicines coalition today (World Cancer Day) show that 3 out of the 5 most expensive cancer medicines brought by ...
Cancer Drugs Sold for 25 Times R&D Costs
A new medical study has found that the latest new cancer drugs are being sold for many times the costs spent developing them; resulting in mega profits for the drug companies who own them and restricted access to these drugs for only the wealthiest patients and healthcare providers.
Is Cancer Research Money Well Spent?
When we give money to cancer research charities like Cancer Research UK we expect that money to be used efficiently but less than 2% is likely to be spent on researching new drugs that can be given to NHS cancer patients as a routine treatment.
Time To Rethink How We Pay for Medical Research
Our medical R&D system is undermining our health – reform could boost our economy and our wellbeing. It’s time we implemented a new, more efficient, collaboratively driven, open innovation model with patient needs at its heart.
Are We Being Misled On Cancer Progress?
Evidence has come to light that the public may be being misled about our progress on beating cancer and that progress is almost certainly not as good as that implied by the much touted cancer survival statistics.
95% of Promising Cancer Research Fails
The British public pays £2.5bn a year towards the cost of developing new drugs for cancer, but 95% of cancer research discoveries don't work in patients and half of the 5% that do the NHS can't afford. Is this money well spent?
Cancer Drug Benefits Are Overhyped
Barely a month goes by without a newspaper headline hailing the latest “Major cancer breakthrough”, but dig beneath the media hype and you’ll discover the shocking reality that new cancer drugs for most cancers are only expected to improve patient survival by just 2.7 months on average.